CG Oncology, Inc. (NASDAQ:CGON) Forecasted to Post FY2024 Earnings of ($1.77) Per Share

CG Oncology, Inc. (NASDAQ:CGON) – Equities research analysts at Lifesci Capital cut their FY2024 earnings estimates for shares of CG Oncology in a research report issued to clients and investors on Tuesday, April 23rd. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings per share of ($1.77) for the year, down from their prior forecast of ($1.75). The consensus estimate for CG Oncology’s current full-year earnings is ($1.60) per share. Lifesci Capital also issued estimates for CG Oncology’s FY2025 earnings at ($2.11) EPS and FY2026 earnings at ($1.22) EPS.

Several other research firms have also recently weighed in on CGON. Cantor Fitzgerald started coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $75.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of CG Oncology in a report on Thursday, April 4th. The Goldman Sachs Group initiated coverage on CG Oncology in a research note on Tuesday, February 20th. They set a “neutral” rating and a $42.00 price target for the company. Finally, Morgan Stanley assumed coverage on CG Oncology in a research note on Tuesday, February 20th. They issued an “overweight” rating and a $55.00 price objective on the stock.

CG Oncology Trading Up 13.3 %

CGON stock opened at $41.00 on Thursday. The stock has a fifty day moving average of $40.32. CG Oncology has a one year low of $28.55 and a one year high of $50.23.

Insider Activity

In related news, CFO Corleen M. Roche purchased 2,000 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was bought at an average price of $19.00 per share, for a total transaction of $38,000.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares in the company, valued at approximately $38,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CFO Corleen M. Roche purchased 2,000 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was bought at an average cost of $19.00 per share, for a total transaction of $38,000.00. Following the completion of the transaction, the chief financial officer now directly owns 2,000 shares in the company, valued at $38,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Decheng Capital Global Life Sc acquired 400,000 shares of the business’s stock in a transaction on Monday, January 29th. The shares were purchased at an average price of $19.00 per share, for a total transaction of $7,600,000.00. Following the transaction, the insider now directly owns 400,000 shares of the company’s stock, valued at $7,600,000. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 666,472 shares of company stock worth $12,662,968.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.